PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Inc. (PEPG) shares surged over 122% following the release of positive clinical data from the 15 mg/kg dose cohort of its FREEDOM-DM1 Phase 1 SAD study for PGN-EDODM1 in Myotonic Dystrophy Type 1 (DM1). The data indicated a mean splicing correction of 53.7% and greater than dose-proportional increases in splicing correction and muscle concentrations, with the treatment demonstrating general tolerability. Capitalizing on these results, PepGen concurrently priced an offering of 31.25 million shares at $3.20 per share, expecting to raise $100 million in gross proceeds.

Analysis

PepGen Inc. has demonstrated significant clinical progress with its myotonic dystrophy type 1 (DM1) candidate, PGN-EDODM1, triggering a substantial market re-rating. The release of Phase 1 data from the 15 mg/kg dose cohort revealed a mean splicing correction of 53.7%, a figure that shows a greater-than-dose-proportional increase compared to the 12.3% and 29.1% observed at lower doses. This strong dose-response relationship, coupled with a 100% patient response rate in the cohort, provides compelling early evidence of the drug's efficacy. The safety profile appears favorable, with adverse events being generally mild and transient. A single dose-limiting toxicity was noted as a mild, reversible kidney biomarker elevation, but it resolved without intervention and did not lead to study discontinuation, which is a positive signal for tolerability. In response to this de-risking event, the stock surged 122.18% on exceptionally high volume of 53.04 million shares. The company strategically capitalized on this momentum by pricing a $100 million secondary offering at $3.20 per share, significantly strengthening its balance sheet to fund operations through upcoming milestones, including the next data readouts anticipated in Q1 2026.

Key Decisions for Investors

• The strong dose-dependent efficacy and favorable safety profile significantly de-risk the PGN-EDODM1 program, justifying a fundamental re-evaluation of the company's long-term valuation based on this lead asset.
• Investors should note the dilutive impact of the 31.25 million share offering, but recognize that the resulting $100 million in gross proceeds provides a crucial cash runway, mitigating financing risk ahead of the next major clinical catalysts in Q1 2026.
• Given the stock's dramatic price increase and the offering price of $3.20, consider potential consolidation in the near term, while monitoring for any interim updates on the FREEDOM2 study as the next major inflection point is over a year away.